

Most Read This Week
- Updated Results of Belzutifan for Advanced RCC
- Pembrolizumab Plus Axitinib vs Sunitinib as First-Line Therapy for Advanced ccRCC
- Nivolumab Plus Cabozantinib vs Sunitinib in the First-Line Treatment for Advanced RCC
- Association Between DepOR and Clinical Outcomes in Previously Untreated RCC
- Adjuvant Pembrolizumab for Post-Nephrectomy RCC
Recently Updated
- Multidisciplinary Team Referral at Diagnosis for Patients With Nonmetastatic RCC
- Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma
- Pembrolizumab Plus Axitinib vs Sunitinib as First-Line Therapy for Advanced ccRCC
- Adjuvant Pembrolizumab for Post-Nephrectomy RCC
- Durvalumab Alone or With Savolitinib or Tremelimumab in Previously Treated Advanced Clear Cell Renal Cancer